Pfizer (2009) reported that as part of current marketing strategy, it is going for an amalgamation of Pfizer and Wyeth that will organize the largest concerns to protect the expected loss for losing patent of Lipitor in 20 guided with the principle that no further single product would dominate 0% of sales from 202.
Why Lipitor anticipated being in declaim
Leafstedt, Marta & Shinkle (999) mentioned that the Lipitor is an effective but costly anti-cholesterol product designed and developed by Warner-Lambert and merged with Pfizer for co-marketing. One of the motivations for the joint effort was, due to the binding of patent law, Warner-Lambert has the pressure to go for generic by 200, and thus Lipitor goes under the joint development banner with Pfizers calcium supplement. With a hard merger battle, Lipitor became at the heat of Pfizers revenue generation
Rubenstein (2007) pointed out that Pfizer has involved its highest effort to the U.S. Patent and Trademark Office to influence the decision for an extended period of patent protection, but it is due up to 20, so Pfizer went for the court verdict.
Sheraton (2005) argued that the Hi
gh Court upheld the exceptionality of the core patent wrapping with Atorvastatin and Lipitor up to November 20 considering the energetic ingredient, thus the other pharmaceutical companies would be capable of producing the similar drug and this is why Lipitor anticipated being in declaiming.
Company Overview
Pfizer is a research-based international biopharmaceutical business that started its journey in 849 along with merely two staff and it became a public limited company in 942. Its acquisition with Warner-Lambert in July 2000 turned it into one of the industrys biggest pharmaceutical businesses; in April 2003, its acquisition with Pharmacia Corporation took place. It possesses an outstanding product pipeline and its international healthcare collection consists of biologic and little particle drugs, vaccines, and other consumer healthcare products; moreover, the company consists of two divisions- Biopharmaceutical and Diversified. In October 2009, the $60 billion takeovers of Wyeth by Pfizer took place, which gave the company a new strength through which it could dominate the entire global pharmaceutical industry.
Market situation